Lithium containing aluminosilicate glasses
A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO 2 , from 4.00 mol % to 11.00 mol % Al 2 O 3 , from 0.10 mol % to 16.00 mol % Li 2 O, from 0.10 mol % to 12.00 mol % Na 2 O, from 0.00 mol % to 5.00 mol % K 2 O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may be substantially free of B 2 O 3 , SrO, BaO, and ZrO 2 .
1. A glass pharmaceutical package having a glass composition comprising:
from greater than or equal to 68.00 mol % to less than or equal to 81.00 mol % SiO 2 ;
from greater than or equal to 4.00 mol % to less than or equal to 11.00 mol % Al 2 O 3 ;
from greater than or equal to 0.10 mol % to less than or equal to 16.00 mol % Li 2 O;
from greater than or equal to 0.10 mol % to less than or equal to 12.00 mol % Na 2 O;
from greater than or equal to 0.00 mol % to less than or equal to 5.00 mol % K 2 O;
from greater than or equal to 0.10 mol % to less than or equal to 8.00 mol % MgO;
from greater than or equal to 0.10 mol % to less than or equal to 5.00 mol % CaO;
from greater than or equal to 0.00 mol % to less than or equal to 0.20 mol % fining agent, wherein
the glass pharmaceutical package is delamination resistant,
the glass pharmaceutical package has class 1 or class 2 chemical durability in acid, base, and water,
the amount of Li 2 O relative to the total alkali metal content is from greater than or equal to 60% to less than or equal to 70%, and
the amount of Na 2 O to the total alkali metal content is from greater than or equal to 12% to less than or equal to 22%.
2. The glass pharmaceutical package according to claim 1 , wherein the glass composition comprises greater than 0.00 mol % of the fining agent, and the fining agent is selected from the group consisting of SnO 2 , CeO 2 , As 2 O 3 , Sb 2 O 3 , Cl − , S − , F − , or Fe 2 O 3 .
3. The glass pharmaceutical package according to claim 2 , wherein the fining agent consists of SnO 2 .
4. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is substantially free of at least one of B 2 O 3 , SrO, BaO, ZrO 2 .
5. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is substantially free of B 2 O 3 , SrO, BaO, and ZrO 2 .
6. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises from greater than or equal to 1.50 mol % to less than or equal to 16.00 mol % Li 2 O.
7. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises from greater than or equal to 0.10 mol % to less than or equal to 7.50 mol % MgO.
8. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a ratio of (Li 2 O+Na 2 O+K 2 O)/(SiO 2 +Al 2 O 3 ) that is from greater than or equal to 0.05 to less than or equal to 0.50.
9. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a ratio of (Li 2 O+Na 2 O+K 2 O)/(SiO 2 +Al 2 O 3 ) that is from greater than or equal to 0.05 to less than or equal to 0.15.
10. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a density from greater than or equal to 2.25 g/cm 3 to less than or equal to 2.50 g/cm 3 .
11. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a molar volume from greater than or equal to 24.00 cm 3 /mol to less than or equal to 27.00 cm 3 /mol.
12. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package has a delamination factor less than or equal to 10.
13. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a strain point from greater than or equal to 450° C. to less than or equal to 625° C.
14. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises an annealing point from greater than or equal to 500° C. to less than or equal to 675° C.
15. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a softening point from greater than or equal to 750° C. to less than or equal to 950° C.
16. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a coefficient of thermal explanation (CTE) from greater than or equal to 4.20 ppm/° C. to less than or equal to 7.00 ppm/° C.
17. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a Log of liquidus viscosity from greater than or equal to 3.50 poise to less than or equal to 6.00 poise.
18. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a Young's modulus from greater than or equal to 10.00 mpsi to less than or equal to 12.00 mpsi.
19. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a shear modulus from greater than or equal to 4.00 mpsi to less than or equal to 5.00 mpsi.
20. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm 2 to less than or equal to 1.5 mg/dm 2 .
21. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm 2 to less than or equal to 0.7 mg/dm 2 .
22. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm 2 to less than or equal to 175 mg/dm 2 .
23. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm 2 to less than or equal to 75 mg/dm 2 .
24. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μg/g to less than or equal to 100 μg/g.
25. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μg/g to less than or equal to 62 μg/g.
26. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a surface compressive stress of at least 350 MPa.
27. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a depth of compression from greater than or equal to 0.05t to less than or equal to 0.25t.
28. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a central tension from greater than or equal to 5 MPa to less than or equal to 160 MPa.
29. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package comprises a diffusivity of potassium ions at 420° C. is from greater than or equal to 0.50 μm 2 /hr to less than or equal to 15.00 μm 2 /hr.
30. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a stored energy of less than or equal to about 15.00 J/m 2 .
31. The glass pharmaceutical package according to claim 1 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a stored energy of greater than or equal to 17.00 J/m 2 .
32. A glass pharmaceutical package having a glass composition comprising:
from greater than or equal to 68.00 mol % to less than or equal to 81.00 mol % SiO 2 ;
from greater than or equal to 6.10 mol % to less than or equal to 7.00 mol % Al 2 O 3 ;
from greater than or equal to 3.10 mol % to less than or equal to 6.60 mol % Li 2 O;
from greater than or equal to 1.40 mol % to less than or equal to 3.00 mol % Na 2 O;
from greater than or equal to 0.00 mol % to less than or equal to 5.00 mol % K 2 O;
from greater than or equal to 5.10 mol % to less than or equal to 7.50 mol % MgO;
from greater than or equal to 0.10 mol % to less than or equal to 5.00 mol % CaO;
from greater than or equal to 0.00 mol % to less than or equal to 0.20 mol % fining agent, wherein
the glass pharmaceutical package is delamination resistant,
the glass pharmaceutical package has class 1 or class 2 chemical durability in acid, base, and water,
the glass pharmaceutical package is substantially free of 8203, SrO, BaO, and ZrO 2 ,
the amount of Li 2 O relative to the total alkali metal content is from greater than or equal to 60% to less than or equal to 70%, and
the amount of Na 2 O to the total alkali metal content is from greater than or equal to 12% to less than or equal to 22%.
33. The glass pharmaceutical package according to claim 32 , wherein the glass composition comprises greater than 0.00 mol % of the fining agent, and the fining agent is selected from the group consisting of SnO 2 , CeO 2 , As 2 O 3 , Sb 2 O 3 , Cl − , S − , F − , or Fe 2 O 3 .
34. The glass pharmaceutical package according to claim 33 , wherein the fining agent consists of SnO 2 .
35. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a ratio of (Li 2 O+Na 2 O+K 2 O)/(SiO 2 +Al 2 O 3 ) that is greater than or equal to 0.05 to less than or equal to 0.50.
36. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package a ratio of (Li 2 O+Na 2 O+K 2 O)/(SiO 2 +Al 2 O 3 ) that is greater than or equal to 0.05 to less than or equal to 0.15.
37. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a density from greater than or equal to 2.25 g/cm 3 to less than or equal to 2.50 g/cm 3 .
38. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a molar volume from greater than or equal to 24.00 cm 3 /mol to less than or equal to 27.00 cm 3 /mol.
39. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package has a delamination factor less than or equal to 10.
40. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a strain point from greater than or equal to 450° C. to less than or equal to 625° C.
41. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises an annealing point from greater than or equal to 500° C. to less than or equal to 675° C.
42. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a softening point from greater than or equal to 750° C. to less than or equal to 950° C.
43. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a coefficient of thermal expansion (CTE) from greater than or equal to 4.20 ppm/° C. to less than or equal to 7.00 ppm/° C.
44. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a Log of liquidus viscosity from greater than or equal to 3.50 poise to less than or equal to 6.00 poise.
45. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a Young's modulus from greater than or equal to 10.00 mpsi to less than or equal to 12.00 mpsi.
46. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a shear modulus from greater than or equal to 4.00 mpsi to less than or equal to 5.00 mpsi.
47. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm 2 to less than or equal to 1.5 mg/dm 2 .
48. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm 2 to less than or equal to 0.7 mg/dm 2 .
49. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm 2 to less than or equal to 175 mg/dm 2 .
50. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm 2 to less than or equal to 75 mg/dm 2 .
51. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μg/g to less than or equal to 100 μg/g.
52. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μg/g to less than or equal to 62 μg/g.
53. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a surface compressive stress of at least 350 MPa.
54. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises is strengthened by ion exchange and a depth of compression from greater than or equal to 0.05t to 0.25t.
55. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a central tension from greater than or equal to 5 MPa to less than or equal to 160 MPa.
56. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package comprises a diffusivity of potassium ions at 420° C. is from greater than or equal to 0.50 μm 2 /hr to less than or equal to 15.00 μm 2 /hr.
57. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a stored energy of less than or equal to about 15.00 J/m 2 .
58. The glass pharmaceutical package according to claim 32 , wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a stored energy of greater than or equal to 17.00 J/m 2 .